Lysine-specific Demethylase 1 and Salt-sensitivity in Humans

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Brigham and Women's Hospital to Brigham and Women's Hospital Show 5 more changesShow less
    • Study completion pushed from Jun 1, 2026 to Jun 1, 2027
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
    • Publications: details revised at 4 of 4 entries
    • Eligibility criteria expanded, about 2 words
  2. Study completion date: Jan 2, 2025 to Jun 1, 2026v5
  3. Study completion date: Jan 2, 2024 to Jan 2, 2025v4
  4. Primary completion date changed from estimate of Jan 2, 2021 to Jan 2, 2022
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 2, 2022 to Jan 2, 2024
    • Site details revised
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jan 2021 to Jan 2, 2021
    • Study completion date: Jan 2022 to Jan 2, 2022
    • Start date: Jan 2017 to Jan 2, 2017
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure, focusing on the salt-sensitive regulatory enzyme Lysine-specific demethylase 1.
Trial Details
NCT Number NCT03029806
Lead Sponsor Brigham and Women's Hospital
Conditions
(from sponsor)		 Healthy Subjects
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov